Open AccessThis article is
- freely available
HIV-1 Protease: Structural Perspectives on Drug Resistance
Department of Biology, Molecular Basis of Disease Program, Georgia State University, Atlanta, GA 30303, USA
* Author to whom correspondence should be addressed.
Received: 1 October 2009; in revised form: 30 November 2009 / Accepted: 1 December 2009 / Published: 3 December 2009
Abstract: Antiviral inhibitors of HIV-1 protease are a notable success of structure-based drug design and have dramatically improved AIDS therapy. Analysis of the structures and activities of drug resistant protease variants has revealed novel molecular mechanisms of drug resistance and guided the design of tight-binding inhibitors for resistant variants. The plethora of structures reveals distinct molecular mechanisms associated with resistance: mutations that alter the protease interactions with inhibitors or substrates; mutations that alter dimer stability; and distal mutations that transmit changes to the active site. These insights will inform the continuing design of novel antiviral inhibitors targeting resistant strains of HIV.
Keywords: protease inhibitors; drug resistance; aspartic protease; molecular mechanism; darunavir
Citations to this Article
Cite This Article
MDPI and ACS Style
Weber, I.T.; Agniswamy, J. HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses 2009, 1, 1110-1136.
Weber IT, Agniswamy J. HIV-1 Protease: Structural Perspectives on Drug Resistance. Viruses. 2009; 1(3):1110-1136.
Weber, Irene T.; Agniswamy, Johnson. 2009. "HIV-1 Protease: Structural Perspectives on Drug Resistance." Viruses 1, no. 3: 1110-1136.